Utilization of lipopolysaccharide challenge in cynomolgus macaques to assess IL-10 receptor antagonism. (1st January 2019)

• Record Type: Journal Article
• Authors: Kamperschroer, Cris; Goldstein, Richard; Schneider, Patricia A.; Kuang, Bing; Eisenbraun, Michael D.
• Is Part Of: Journal of immunotoxicology. Volume 16:Number 1(2019)
• Page Start: 164
• Page End: 172
• Publication Date: 2019-01-01
• Subjects: Animal model -- cytokines -- cynomolgus macaque -- IL-10 -- immunomodulatory -- innate immune response -- lipopolysaccharide (LPS) -- monkey -- non-clinical -- non-human primate; Immunotoxicology -- Periodicals; Poisons -- Immunology -- Periodicals; Environmental health -- Periodicals; 616.97
• DOI: 10.1080/1547691X.2019.1656683
• Languages: English
• ISSNs: 1547-691X

Abstract

Abstract: The current era of drug discovery has been marked by a significant increase in the development of immune modulating agents to address a range of diseases such as cancer, chronic inflammation, and other conditions of dysregulated immunity. Non-clinical evaluation of these agents in animal models can be challenging, as the presence of an active immune state is often required in order to detect the effects of the test agent. Modulation of interleukin (IL)-10 signaling represents this type of situation in that altering IL-10 action in vivo can be difficult to appreciate in the absence of an ongoing immune response. The study presented here reports on the use of lipopolysaccharide (LPS) challenge in cynomolgus macaques to induce predictable inflammatory cytokine responses. The results showed that IL-10 receptor (IL-10R) blockade with an antagonist monoclonal antibody (mAb) dramatically enhanced the LPS-induced cytokine response, thus demonstrating in vivo pharmacologic activity of this immunomodulatory antibody. We submit that this approach could be applied to other cases where the intent of a candidate therapeutic is to modulate components of inflammatory cytokine responses.